Global Polycystic Ovary Syndrome (PCOS) Treatment Market

Report ID : 1455 | Published : 2022-11-22 | Pages: | Format: PDF/EXCEL

The market size of the Global Polycystic Ovary Syndrome (PCOS) Treatment Market in the year 2021 is valued at 3.41 billion and is predicted to reach 5.26 billion by the year 2030 at an 5.13% CAGR during the forecast period.

Women of childbearing age frequently have polycystic ovarian syndrome (PCOS), a hormonal disorder. Menstrual cycles that are irregular or prolonged, as well as excessive levels of male hormones, might be caused by PCOS. There is no known treatment for PCOS, but several medications control its symptoms and menstrual cycle. An increase in PCOS prevalence, an increase in patient population knowledge, and an increase in the use of combination therapy are the major factors driving the growth of the polycystic ovarian syndrome treatment market. Advances in PCOS screening technology, the rise in demand for PCOS medications, and the accessibility of PCOS treatment also impact the market's expansion. However, it is anticipated that market growth will be constrained by the lack of approved treatments and PCOS's uncertain pathophysiology and etiology.

Additionally, during the projected period, the unrealized potential of developing economies presents lucrative market growth opportunities. As the prevalence of polycystic ovarian syndrome (PCOS) rises, so is the need for treatment. However, the absence of specialized treatment for PCOS disease is anticipated to impede market expansion.

Market Segmentation:

The polycystic ovary syndrome (PCOS) treatment market is segmented on the drug class and distribution channel. Based on drug class, the market is segmented into oral contraceptives, insulin sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs and diuretics. Based on distribution channel, polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, drug stores/OTC, e-commerce and clinics.

Based on drug class, the insulin sensitizing agents segment is accounted as a major contributor to the polycystic ovary syndrome (PCOS) treatment market.

Based on drug class, the market is segmented into oral contraceptives, insulin-sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs and diuretics. The insulin-sensitizing agent's category grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. Numerous items are offered for sale, including Glucophage X.R. (Metformin) and other items that contain Troglitazone, Rosiglitazone, and Pioglitazone. Metabolic dysfunction in PCOS may cause an overproduction of androgen, impacting insulin secretion and raising the risk of diabetes. As a result, insulin-sensitizing drugs are crucial for therapeutics because they balance hormone levels, lower insulin levels, and reduce ovarian androgen production.

The e-commerce retailing segment witnessed growth at a rapid rate.

Based on the distribution channel, the polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, drug stores/OTC, e-commerce and clinics. The e-commerce category is anticipated to grow significantly over the forecast period because more people prefer buying medicines online over traditional means, more people are aware of online sources, and more people are using the internet.

The Asia Pacific polycystic ovary syndrome (PCOS) treatment market holds a significant revenue share in the region.

The Asia Pacific polycystic ovary syndrome (PCOS) treatment market is expected to register the highest market share in revenue shortly. The market will expand due to the rising acceptance of products for treating polycystic ovarian syndrome and increased knowledge of the treatment. The development of the R&D sector, the expansion of the target population, the growth of healthcare reforms, and technological developments in the healthcare industry all contribute to the market's expansion. Additionally, North America is anticipated to expand at a significant rate over the course of the forecast period. Factors like the increased focus of major manufacturers on growing their geographic presence in developing Asia-Pacific nations to seize a large population base, high growth opportunities in the market, and high disposable incomes are also anticipated to propel the growth of the market in the region.

Competitive Landscape

The key players in the polycystic ovary syndrome (PCOS) treatment market have shifted their focus toward product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance their product portfolio and strengthen their global market footprint. Some major key players in the polycystic ovary syndrome (PCOS) treatment market are Novartis AG, Sanofi, Teva Pharmaceutical Industries Limited, Merck & Co., Inc. (Merck group), AstraZeneca plc., Bayer AG. Abbott, Pfizer, Inc, Bristol-Myer Squibb Company, Ferring Pharmaceuticals, Inc., Johnson and Johnson, Mylan N.V., Allergan plc., GlaxoSmithKline, Lupin Pharmaceuticals, AbbVie, Takeda, BIOCAD Global, Blairex Laboratories Inc and Agile Therapeutics.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Snapshot

Chapter 4. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Drug Class Estimates & Trend Analysis

5.1. by Drug Class & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Drug Class:

5.2.1. Oral Contraceptives

5.2.2. Insulin Sensitizing Agents

5.2.3. Antidepressants

5.2.4. Ornithine Decarboxylase Inhibitors

5.2.5. Aromatase Inhibitors & SERMs

5.2.6. Diuretics

Chapter 6. Market Segmentation 2: by Distribution channel Estimates & Trend Analysis

6.1. by Distribution channel & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Distribution channel:

6.2.1. Hospital Pharmacies

6.2.2. Drug Stores/OTC

6.2.3. e-Commerce

6.2.4. Clinics

Chapter 7. Polycystic Ovary Syndrome (PCOS) Treatment Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2030

7.1.2. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution channel, 2019-2030

7.1.3. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2030

7.2. Europe

7.2.1. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2019-2030

7.2.2. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2019-2030

7.2.3. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2019-2030

7.3.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2019-2030

7.3.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2019-2030

7.4.2. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2019-2030

7.4.3. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Drug Class, 2019-2030

7.5.2. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by Distribution channel, 2019-2030

7.5.3. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

 8.2.1.

8.2.2. Novartis AG

8.2.3. Sanofi

8.2.4. Teva Pharmaceutical Industries Limited

8.2.5. Merck & Co., Inc. (Merck group)

8.2.6. AstraZeneca plc.

8.2.7. Bayer AG

8.2.8. Abbott

8.2.9. Pfizer, Inc

8.2.10. Bristol-Myer Squibb Company

8.2.11. Ferring Pharmaceuticals, Inc.

8.2.12. Johnson and Johnson

8.2.13. Mylan N.V.

8.2.14. Allergan plc.

8.2.15. GlaxoSmithKline

8.2.16. Lupin Pharmaceuticals

8.2.17. AbbVie

8.2.18. Takeda

8.2.19. BIOCAD Global

8.2.20. Blairex Laboratories Inc

8.2.21. Agile Therapeutics

8.2.22. Other Prominent Players

By Drug Class-

  • Oral Contraceptives
  • Insulin Sensitizing Agents
  • Antidepressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs
  • Diuretics

By Distribution channel-

  • Hospital Pharmacies
  • Drug Stores/OTC
  • e-Commerce
  • Clinics

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients